Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-03T05:26:06.054Z Has data issue: false hasContentIssue false

1501 – Early Effects Of Agomelatine On Self-referential Processing In Acute Depressed Patients: a Fmri Study

Published online by Cambridge University Press:  15 April 2020

P. Fossati
Affiliation:
Psychiatry, CNRS USR 3246 & CR-ICM & APHP GH Pitié Salpétrière, Paris
M. Jabourian
Affiliation:
Neuroscience ISIS, Servier, Suresnes
J. Laredo
Affiliation:
Neuroscience ISIS, Servier, Suresnes
N. Allailli
Affiliation:
Psychiatry, CNRS USR 3246 & CR-ICM & APHP GH Pitié Salpétrière, Paris
S. Lehericy
Affiliation:
Neuroradiology, CENIR & CR-ICM
P. Delaveau
Affiliation:
Psychiatry, CNRS USR 3246 & CR-ICM, Paris, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Increased Self-focus, the tendency to excessively appraise stimuli as strongly related to oneself, is a core feature of major depression. In major depressive disorder increased self-focus is associated with abnormal dorsal and ventral medial prefrontal activity as well as increased dorsolateral prefrontal activity.

Objective

Although Lemogne et al, 2010 suggested that Medial Prefrontal Activity does not change after reduction of depressive symptoms, sensitivity of brain regions involved in self-referential processing to antidepressant is unknown. The main goal here was to assess with fMRI early effects of agomelatine, on self-referential processing in depressed patients.

Methods

25 acute depressed patients and 14 healthy controls were scanned before and after 7 days treatment, while performing self-referential processing task using emotional pictures. Patients were randomized to agomelatine 25mg/day (n=13) or placebo (n=12), healthy controls received placebo. Subjects were asked to evaluate pictures according to different conditions: Self (Does the picture relate to you?); General (Is the picture positive or negative?). Depression was assessed with Hamilton Scale.

Results

Depressed patients compared to controls at baseline showed hyperactivity in dorsolateral prefrontal cortex, dorsal anterior cingulate and ventrolateral prefrontal cortex (VLPFC). After 7 days treatment, Agomelatine, compared to placebo, normalized the hyperactivity of VLPFC to healthy volunteers’ level.

Conclusion

Agomelatine targets specific brain structures, namely VLPFC, involved in automatic regulation of emotion during self-referential processing. These changes in brain activity at day 7 could contribute to the early clinical effects of agomelatine, suggesting an early set up of the brain for long term response and remission of depression.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.